Dosage Forms & Drug Delivery Systems – Page 52

Post-Approval Change Failure during FDA inspection: risk assessment and change control template

Identifying symptoms of a post-approval change failure is critical in initiating timely investigations. Here are some common signals that may indicate issues during production or quality control processes:Click to read…

Cleaning Validation Gap during inspection preparation: E&L risk assessment and documentation

Understanding the initial signals of a potential cleaning validation gap is crucial for timely corrective measures. Common symptoms may include:Click to read the full article.

Regulatory Classification Issue during PAI readiness: risk assessment and change control template

Recognizing the signs of regulatory classification issues is crucial to initiating an effective response. Symptoms may manifest in various contexts such as during production, quality control testing, or regulatory audits.…

Complaint Handling Deficiency during lifecycle management: ownership between drug GMP and device QMS

Identifying the symptoms or signals related to a complaint handling deficiency is the first step towards addressing the underlying problem. Symptoms can manifest in various ways, including:Click to read the…

Fine Particle Fraction Drift during EU/UK launch supply: E&L risk assessment and documentation

The first step in addressing fine particle fraction drift is recognizing the symptoms or signals that indicate a deviation from acceptable standards. Common signs may include:Click to read the full…

Assembly Process Validation Failure for combination drug products: risk assessment and change control template

Validation failures often manifest through observable symptoms that may initially appear as minor deviations but can signify deeper issues within the assembly process. Key symptoms to monitor include:Click to read…

Assembly Process Validation Failure during lifecycle management: batch release impact and documentation pack

When facing an assembly process validation failure, recognizing initial symptoms on the manufacturing floor or in the lab is critical. Symptoms can manifest as deviations from standard operating procedures (SOPs),…

Design Controls Deficiency during EMA/MHRA review: ownership between drug GMP and device QMS

Identifying symptoms or signals that indicate a design controls deficiency is a critical first step in the investigation process. These signals may manifest in various ways, and recognizing them early…

Spray Pattern Failure during inspection preparation: method variability vs true product failure assessment

Understanding Spray Pattern Failures: A Comprehensive Investigation Approach In pharmaceutical manufacturing, ensuring the consistency and reliability of dosage forms is critical. One such challenge arises during the production of inhalation…

Software Validation Gap for drug-device combination products: batch release impact and documentation pack

When a software validation gap occurs, various symptoms may emerge that signal a need for immediate investigation. These symptoms can manifest on the manufacturing floor or within the laboratory environment:Click…

Supplier Qualification Gap during EMA/MHRA review: ownership between drug GMP and device QMS

Understanding Supplier Qualification Gaps in EMA and MHRA Reviews: A Comprehensive Investigation In the complex landscape of pharmaceutical manufacturing, ensuring compliance across various regulatory bodies such as EMA and MHRA…

Delivered Dose Uniformity Failure after device supplier change: method variability vs true product failure assessment

Identifying symptoms or signals of delivered dose uniformity failures is the first step in managing and rectifying the situation. These symptoms may arise during various stages of production or quality…